# Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

> **NCT02508038** · PHASE1 · RECRUITING · sponsor: **University of Wisconsin, Madison** · enrollment: 22 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Myelodysplastic Syndrome
- Myeloproliferative Syndrome
- Rhabdomyosarcoma
- Ewing Sarcoma
- Primitive Neuroectodermal Tumor
- Osteosarcoma
- Neuroblastoma

## Interventions

- **PROCEDURE:** TCRαβ+/CD19+ depleted Haploidentical HSCT
- **DRUG:** Zoledronate

## Key facts

- **NCT ID:** NCT02508038
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-02-12
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02508038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02508038, "Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT02508038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*